Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005755 · ClinicalTrials.gov registry record · Phase 3
Maxigesic® IV Phase 3 Exposure Study
A Phase 3 study, sponsored by AFT Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT04005755 is a Phase 3 study that has completed, run by AFT Pharmaceuticals. The registered enrollment target is 232 participants.
The verdict
NCT04005755, a Phase 3 study, has completed, sponsored by AFT Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
Interventions
- DRUG Maxigesic® IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04005755
The ClinicalTrials.gov registry entry for NCT04005755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AFT Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maxigesic® IV is the first listed.
NCT04005755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04005755 about?
NCT04005755 is a clinical study titled "Maxigesic® IV Phase 3 Exposure Study". The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
What is the current status of trial NCT04005755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2019-07-22. Estimated completion is 2020-07-07.
What interventions are being tested in trial NCT04005755?
The interventions under investigation include: Maxigesic® IV (DRUG).
Who is sponsoring clinical trial NCT04005755?
This trial is sponsored by AFT Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.